Previous 10 | Next 10 |
Dr. Adam M. Brufsky of University of Pittsburgh School of Medicine and Dr. Saranya Chumsri of Mayo Clinic will discuss the current treatment landscape for patients with advanced metastatic breast cancer and the latest clinical data of the Bria-IMT™ regimen BriaCell recently rep...
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform canc...
The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician’s choice therapy (1:1) Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria...
2023-09-13 09:00:30 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food and Drug Administr...
2023-09-10 00:26:34 ET Summary BriaCell Therapeutics is developing a cell therapy vaccine for breast cancer using a research cell line that has been used for decades. The company's main therapeutic candidate, Bria-IMT, has shown preliminary safety and efficacy in clinical trials, ...
2023-09-08 15:09:33 ET More on Briacell Seeking Alpha’s Quant Rating on Briacell Therapeutics Historical earnings data for Briacell Therapeutics Financial information for Briacell Therapeutics For further details see: BriaCell falls after Phase 2 d...
Median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature) 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's co...
BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement. TORONTO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology...
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...
August 31, 2023 is the expected effective date for the distribution contemplated by the Arrangement. PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-sta...
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Corp. Company Name:
BCTX Stock Symbol:
NASDAQ Market:
BriaCell Therapeutics Corp. Website:
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...